Diet showdown: mediterranean vs DASH for fatty liver
NCT ID NCT07622680
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tested whether Mediterranean or DASH diets improve liver function in people with nonalcoholic fatty liver disease (NAFLD). 75 adults with mild to moderate liver enzyme elevations were split into three groups: one following general dietary guidelines, one on a Mediterranean diet, and one on a DASH diet. Researchers measured body mass index and liver enzymes before and after the diet period to see which approach worked best.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Mediterranean diet and DASH diet
- What this could lead to
- If successful, this could show that specific diets like Mediterranean or DASH help manage NAFLD and improve liver health without medication.
- What could go wrong
- This is a small, completed study with 75 participants, so results may not apply to everyone. Dietary changes can be hard to maintain long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEP A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Lahore
Lahore, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common b vitamin tame fatty liver?
- Could a daily dose of citrus fiber tame fatty liver inflammation?
- Stick-On ultrasound patch could spot liver damage without a specialist
- New portable scanner could replace needle biopsies for fatty liver disease
- New scan reveals hidden metabolic clues in fatty liver disease
- Which diabetes drug fights fatty liver better? new study pits dapagliflozin against empagliflozin